Avadel Pharmaceuticals PLC reports results for the quarter ended June 30 - Earnings Summary

Avadel Pharmaceuticals

07/08/2025 18:12

Avadel Pharmaceuticals PLC AVDL.OQ reported quarterly adjusted earnings of 10 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -14 cents.  The mean expectation of eight analysts for the quarter was for earnings of 3 cents per share. Wall Street expected results to range from zero cents to 5 cents per share.

Revenue rose 64.2% to $68.13 million from a year ago; analysts expected $61.50 million.

Avadel Pharmaceuticals PLC's reported EPS for the quarter was 10 cents​.

The company reported quarterly net income of $9.67 million.

Avadel Pharmaceuticals PLC shares had risen by 25.4% this quarter and gained 5.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 97% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $16.50, about 32.7% above its last closing price of $11.10

This summary was machine generated from LSEG data August 7 at 05:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.03
0.10
Beat
Mar. 31 2025
-0.07
-0.05
Beat
Dec. 31 2024
-0.04
-0.05
Missed
Sep. 30 2024
-0.06
-0.03
Beat